Investigational drug · Phase 2
CU06-1004
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for DME, Diabetic Macular Edema, Diabetic Macular Edema (DME).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "CU06-1004"
First trial start
2026
Dec 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CU06-1004", any sponsor or status.
Conditions studied
As listed on its trial records.
- DME
- Diabetic Macular Edema
- Diabetic Macular Edema (DME)
Approved drugs for the same conditions: Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "CU06-1004" as an intervention, largest first.
- Study of CU06-1004 in Patients With Daibetic Macular EdemaPivotal-lookingNot yet recruiting
Curacle Co., Ltd.Industry
NCT07459829 · 156 participants (planned) · Start Dec 1, 2026 · Primary completion Jan 1, 2028
Drug: CU06-1004; Placebo Control · For: DME; Diabetic Macular Edema; Diabetic Macular Edema (DME)
Curacle Co., Ltd.Industry
NCT04795037 · 81 participants · Start Jul 15, 2021 · Primary completion Mar 2, 2022
Drug: CU06-1004, Single dose; CU06-1004, Multiple doses and 1 more · For: Diabetic Macular Edema
Sites: Lincoln, Nebraska
Curacle Co., Ltd.Industry
NCT05573100 · 67 participants · Start Dec 21, 2022 · Primary completion May 31, 2023
Drug: CU06-1004 · For: Diabetic Macular Edema
Sites: Deerfield Beach, Florida; Baltimore, Maryland; Hagerstown, Maryland · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Commentary: CU06-1004 inhibits the progression of chronic colitis and colitis-associated colorectal cancer by suppressing inflammation.
Guo W, Wang Y, Fang D, et al. · Front Pharmacol 2025
- CU06-1004 inhibits the progression of chronic colitis and colitis-associated colorectal cancer by suppressing inflammation.
Kim D, Kim Y, Zhang H, et al. · Front Pharmacol 2025
- CU06-1004 alleviates oxidative stress and inflammation on folic acid-induced acute kidney injury in mice.
Bae CR, Kim Y, Kwon YG · J Pharmacol Sci 2024
- CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome.
Park S, Lee S, Kim D, et al. · Front Pharmacol 2023
- CU06-1004 alleviates vascular hyperpermeability in a murine model of hereditary angioedema by protecting the endothelium.
Lee S, Kim Y, Kim YS, et al. · Allergy 2023
- Efficacy of CU06-1004 via regulation of inflammation and endothelial permeability in LPS-induced acute lung injury.
Kim Y, Bae CR, Kim D, et al. · J Inflamm (Lond) 2023
Also in development for DME
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.